September 17, 2014 6:58 PM ET


Company Overview of Advinus Therapeutics Limited

Company Overview

Advinus Therapeutics Limited, a research-based pharmaceutical company, provides drug discovery, and pharmaceutical and agrochemical development services in India. The company’s drug discovery services include developing small molecule therapies for indications in metabolic diseases, such as diabetes and obesity; inflammatory diseases, including chronic obstructive pulmonary diseases, inflammatory bowel diseases, and autoimmune disorders; pain/degenerative diseases, which comprise Parkinson’s diseases; and neglected diseases, such as leishmaniasis, dengue fever, tuberculosis, leprosy, and malaria. Its pharmaceutical development services include process development and synthesis, process chemi...

21 & 22 Phase II

Peenya Industrial Area

Bengaluru,  560 058


Founded in 2005


91 80 2839 4959


91 80 2839 4015

Key Executives for Advinus Therapeutics Limited

Chief Executive Officer
Chief Scientific Officer and Executive Vice President of Drug Discovery
Senior Vice President and Head of Pharmaceuticals & Agrochemical Development
Head of Corporate Quality Assurance and Vice President
Chief of Technical Operations
Compensation as of Fiscal Year 2014.

Advinus Therapeutics Limited Key Developments

Advinus Therapeutics Limited Reports Unaudited Earnings Results for the Year Ended March 31, 2014

Advinus Therapeutics Limited reported unaudited earnings results for the year ended March 31, 2014. For the period, the company reported revenue was INR 1,544,976,958 against INR 1,290,716,834 a year ago. Earnings before interest, tax, depreciation and amortization was INR 114,844,726 against INR 133,691,107 a year ago. Loss before tax was INR 367,775,831 against INR 317,501,464 a year ago. Loss after tax was INR 367,775,831 against INR 317,501,464 a year ago. Loss per share was INR 2.75 against INR 2.38 a year ago. Net cash generated from operating activities was INR 248,516,688 against INR 22,841,186 a year ago. Capital expenditure on fixed assets, including capital advance was INR 80,621,764 against INR 26,436,734 a year ago.

Advinus Therapeutics Limited Reports Earnings Results for the Six Months Ended September 30, 2013

Advinus Therapeutics Limited reported earnings results for the six months ended September 30, 2013. For the period, the company reported net income from sales and services was INR 660.924 million against INR 371.129 million a year ago. Profit from operations was INR 37.858 million against loss of INR 229.229 million a year ago. Net loss was INR 89.297 million against INR 368.884 million a year ago. Loss per share was INR 0.67 against INR 2.76 a year ago.

Advinus Therapeutics Limited, Board Meeting, Oct 17, 2013

Advinus Therapeutics Limited, Board Meeting, Oct 17, 2013. Agenda: To consider unaudited earnings results for the six months ended September 30, 2013.

Similar Private Companies By Industry

Company Name Region
Virchow Drugs Ltd. Asia
Zuventus Healthcare Ltd Asia
Sunbeam Remedies Pvt. Ltd. Asia
Lyka Exports Ltd. Asia
Bayer Zydus Pharma Private Limited Asia

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Advinus Therapeutics Limited, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at